Erlotinib plus tivantinib versus erlotinib alone in patients with previously treated stage IIIb/IV non–small-cell lung cancer: A meta-analysis based on randomized controlled trials

BACKGROUND: Whether erlotinib plus tivantinib (ET) can achieve better clinical benefits than erlotinib plus placebo (EP) among participants with previously treated advanced non-small-cell lung cancer (NSCLC) is still disputed. We conducted a meta-analysis to evaluate the anticancer efficacy and safe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medicine (Baltimore)
Hauptverfasser: Deng, Huan, Wang, Li, Chen, Xinling, Zhang, Shujuan, Yi, Fengming, Wei, Yiping, Zhang, Wenxiong
Format: Artigo
Sprache:Inglês
Veröffentlicht: Wolters Kluwer Health 2020
Schlagworte:
5700
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7313549/
https://ncbi.nlm.nih.gov/pubmed/32569187
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000020596
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge